The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands .   This product was eventually discontinued and replaced in the United States with a new product named Oxandrin, which is the sole remaining brand name for oxandrolone in the United States.   Oxandrolone has also been sold under the brand names Antitriol ( Spain ), Anatrophill ( France ), Lipidex ( Brazil ), Lonavar ( Argentina , Australia , Italy ), Protivar, and Vasorome ( Japan ) among others.     Additional brand names exist for products that are manufactured for the steroid black market. 
There are no head to head studies comparing Fasenra, Nucala and Cinqair, and likely there will never be. It would be up to the physician and patient to discuss the pros and cons of each medication to determine which treatment course is best. The price tag for these medications are somewhere between $2000-3000/month before insurance. Insurance companies have strict criteria before approving these medications. What kind of insurance coverage a patient has also may also determine which of these medications a patient with severe eosinophilic asthma needs to try first. AstraZeneca will most likely have patient support programs to help with copays for those whose insurances give only partial coverage. Other medications that AstraZeneca uses for milder or more moderate cases of asthma include, Accolate (zafirlukast), Pulmicort (budesonide) and Symbicort (budesonide/formoterol).